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ABSTRACT
Introduction: Congestive heart failure is a significant
cause of morbidity and mortality in Australia. Accurate
data for the Northern Territory and Indigenous
Australians are not presently available. The economic
burden of this chronic cardiovascular disease is felt by
all funding bodies and it still remains unclear what
impact current measures have on preventing the
ongoing disease burden and how much of this filters
down to more remote areas. Clear differentials also exist
in rural areas including a larger Indigenous community,
greater disease burden, differing aetiologies for heart
failure as well as service and infrastructure
discrepancies. It is becoming increasingly clear that
urban solutions will not affect regional outcomes. To
understand regional issues relevant to heart failure
management, an understanding of the key performance
indicators in that setting is critical.
Methods and analysis: The Northern Territory Heart
Failure Initiative—Clinical Audit (NTHFI-CA) is a
prospective registry of acute heart failure admissions over
a 12-month period across the two main Northern
Territory tertiary hospitals. The study collects information
across six domains and five dimensions of healthcare.
The study aims to set in place an evidenced and
reproducible audit system for heart failure and inform the
developing heart failure disease management
programme. The findings, is believed, will assist the
development of solutions to narrow the outcomes divide
between remote and urban Australia and between
Indigenous and Non-Indigenous Australians, in case they
exist. A combination of descriptive statistics and mixed
effects modelling will be used to analyse the data.
Ethics and dissemination: This study has been
approved by respective ethics committees of both the
admitting institutions. All participants will be provided a
written informed consent which will be completed prior
to enrolment in the study. The study results will be
disseminated through local and international health
conferences and peer reviewed manuscripts.
INTRODUCTION
The congestive heart failure (CHF) syndrome
is the leading cause for admissions and is in the
top three causes for mortality in the Western
World. It is associated with signiﬁcant morbidity,
impacts on individual’s quality of life and
through the necessity of frequent medical and
allied health interventions, prescription of
pharmacological agents and recurrent hospita-
lisations, is a source of stress on health
resources. Guidelines-based care improves out-
comes but challenges exist in implementation.
Neglecting this resource-intensive investment
leads to poor outcomes and so the cycle
perpetuates. CHF is speculated, as no accurate
prospective data are available, to be higher in
the Northern Territory (NT) and among
Indigenous Australians. The recent Central
Australian Secondary Prevention of Acute
Coronary Syndromes (CASPA) study high-
lighted a signiﬁcant burden of CHF, greater
among the Indigenous communities,1 conﬁrm-
ing earlier studies of under-representation
nationally.2 These works have highlighted
several key indicators relevant to the NT1–26:
1. There is a high burden of CHF that cannot
be explained by traditional risk factors alone.
Among the Indigenous population, given
that social factors inﬂuence the risk of CHF,
the excess in mortality is most likely to be
multifactorial in origin, and have its foun-
dations in the economic, social, physio-
logical, psychological and educational
disadvantages.1–3
2. There appears a greater burden of CHF
related to rheumatic and non-ischaemic aeti-
ology, which is reversible and has a better
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prognosis when treatment is delivered or preventive
measures are enforced.2–5 14
3. There appears a greater burden of CHF with comorbid-
ities among Indigenous clients, which requires greater
resources to deliver comprehensive care.2 15
4. There are signiﬁcant barriers and differentials in access to
appropriate, acceptable and evidence-based medical
care and preventative measures for Indigenous and
remote clients. New delivery methods are important
as CHF can largely be delivered as community-based
care.13–25
5. There is signiﬁcant delay in presentation and receipt of
acute care during periods of decompensation, and
for geographical and other reasons delay of deﬁnitive
therapies or procedures.
6. There is poor uptake of postdischarge services such as
cardiac rehabilitation, and at present, unknown
demographics will assist implementation of remote
allied health or technological-based solutions.3 14
7. Unique geography—the NT consists of a vast area with
two major public hospitals in Alice Springs and
Darwin servicing 230 000 clients; approximately 70%
of people live within the urban proximity. Specialist
services reside at the tertiary hospitals with satellite
district hospitals in several smaller townships support-
ing a small number of visiting specialists. Service
planning must take this into account.3 14
8. External validity—adherence to guidelines early in
hospital admission can improve outcomes; however,
not all groups meet trial conditions in remote areas
nor are trial conditions for dosing strategies reprodu-
cible.15 27 28 A consensus on therapeutics strategies is
needed.
Lack of accurate prospective data for the listed points
makes it difﬁcult to accurately develop a tailored, yet com-
prehensive heart failure (HF) programme. Developing
tools to gather evidence require adhering to standards for
validity and reproducibility, which are also lacking. This
study is focused on understanding the current evidence
base for quantifying healthcare systems and informing the
design of diagnostic and management clinical audits that
would form the backbone for the direction of CHF disease
management systems within an NT context. We thus
propose to study the quality and outcomes of care for
patients admitted with acute decompensated heart failure
(ADHF). We aim to develop key clinical and process of
care performance indicators (key performance indicators,
KPI) and translate these ﬁndings for improved service
delivery if and where deﬁciencies are highlighted. This
paper describes the rationale for the Northern Territory
Heart Failure Initiative—Clinical Audit (NTHFI-CA)
design.
METHODS
Aims and scientific hypotheses
The NTHFI-CA survey was designed with four major
objectives: ﬁrst, to develop validated and reproducible
KPI for the comprehensive measurement of quality of
care and outcomes for clients admitted with ADHF. In
this, we aim to measure for the clients, the proportion
meeting standardised clinical outcomes, process out-
comes and deﬁned targets of secondary prevention and
compare by age, ethnicity, sex and place of usual resi-
dence. For the health system, identify failures of the
health care system in relation to timely acute care and to
the provision of secondary CHF care, particularly for
Indigenous and remote clients; second, to develop a
system of data collection and reporting, that can be used
for ongoing quality assessment and improvement across
the care continuum; third, the results of the ﬁrst two
objectives, are believed, will help tailor a pilot interven-
tion study similar to the ongoing nurse-led intervention
developed around the CASPA-acute coronary syndrome
(ACS) study ﬁndings; fourth, to accumulate sufﬁcient
epidemiology and implementation-focused information
to steer future action in the provision, monitoring and
development of guidelines-based quality CHF care for
rural, urban, Indigenous and Non-Indigenous clients.
We hypothesise that patients presenting with ADHF are
expected to have: a disproportionate representation of
Indigenous clients with advanced systolic impairment;
excess of alcohol, ischaemic or rheumatic aetiology;
greater comorbidities in diabetes, hypertension, lipid
abnormalities and/or renal insufﬁciency, and with other
non-cardiac comorbidities; delayed presentations for
Indigenous and remote clients; we hypothesise that
treatment for Indigenous and remote clients: are likely
suboptimal for the stage of HF; have fewer clinical inter-
ventions and support compared with their urban coun-
terparts; are less likely to receive novel therapeutic
options or enrolled in multicentre trials; and are more
likely to have their HF managed without regular cardi-
ology specialist input.
Projected outcomes
We anticipate several outcomes from this work: ﬁrst, iden-
tiﬁcation of the points of weaknesses in the hospital and
community health centre systems that impact on urban,
rural, Indigenous and Non-Indigenous clients and hope-
fully lead to the development of focused service
improvement models across this care continuum;
second, to link with a number of collaborative research
projects assessing barriers to care for Indigenous clients
suffering with heart diseases; third, lead to the develop-
ment of ongoing and sustainable quality improvement
practices and monitoring within hospital and primary
healthcare (PHC) services across the region; fourth,
help develop, trial and implement standardised medical
discharge summaries and care plans during hospital stay
and following discharge; ﬁfth, explore the potential con-
tribution of poor systems of care to the high level of
illness faced by Indigenous people; and ﬁnally, assess-
ment of the potential barriers that may exist for primary
and secondary prevention for CHF. These goals should
initially drive improved service delivery and subsequently
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provide a baseline for evaluating ongoing service out-
comes on which to base future acute and preventive pro-
gramme development and inform the development of
alternative models of secondary prevention for NT
clients with CHF.
Protocol
The project comprises two speciﬁc stages. Stage 1 is the
collaborative development of suitable KPI covering
process and outcome measures across the continuum of
care; and stage 2, involves two phases, is the development
of appropriate, feasible data collection tools and their
subsequent measurement in hospital and PHC settings.
Development of appropriate clinical indicators (stage 1)
We conducted an extensive literature review with key
words “heart failure or acute heart failure or chronic
heart failure or CHF”; “database or study design or study
rationale or registry” and “Data Collection/or Quality
Indicators, Health Care/ or Management Audit/ or per-
formance indicators.mp or Healthcare Disparities/
Quality Assurance, Health Care/or Quality of Health
Care/or Quality Indicators, Health Care/or quality of
care indicators.mp or ‘Outcome and Process Assessment
(Health Care)’/or process of care.mp”. Published and
established existing KPI for measuring the quality and
outcomes of care for patients experiencing ADHF were
collated6–12 29–40 The CASPA study KPI was used as a
template. Within six domains and ﬁve dimensions of
care, KPI were added or rested on this template using
the American College of Cardiology and the American
Heart Association (ACC/AHA) attributes of perform-
ance measures.31 Addition or removal required consen-
sus of the principal investigator and one co-investigator.
Uniform agreement by all co-investigators was required
for accepting the ﬁnal measures (ﬁgures 1 and 2). ACS
(as an aetiology for ischaemic cardiomyopathies or
aggravator of existing cardiomyopathies) and KPI that
were deemed not to add any additional beneﬁt on what
was already known from CASPA were also rested.
Study design and registry (stage 2)
The NTHFI-CA registry is a prospective observational
cohort study designed to examine the performance of
health systems in relation to the acute management and
secondary prevention of ADHF in patients admitted to
two teaching hospitals in the NT, Royal Darwin Hospital
(RDH) and Alice Springs Hospital (ASH) starting
September 2013 and followed for 12 months ending
September 2015. Performance will be measured against
currently available evidence-based guidelines for the
treatment and secondary prevention of CHF4 6–11.29–38
Data collected will be entered in the NTHFI-CA study
registry located at NT Cardiac Services/Menzies School
of Health Research, Darwin. All documentation relating
to study participants will be treated in accordance with
National Statement of Ethical Conduct in Human
Research.41
Eligibility criteria
Patients admitted to either hospital with the diagnosis of
HF (International Classiﬁcation of Diseases (ICD)-10CM
I42.0–I42.8, 143.0, 150.0–150.9) will be eligible for the
prospective case note audit. The participants will also be
drawn from inpatients who develop acute symptoms
while in hospital for other reasons. Further assessment
will also involve the generation of lists ICD CM I00–I02,
I05–I09, I10–I15, I20–I28, I30–I41, I44–I49, I70–I89 and
I95–I99 (complicated with acute heart failure) for cross-
checking of initial coding and recording of outcome
variables. Participants will be considered eligible if the
review of medical records demonstrates that they, in fact,
have suffered an ADHF based on ACC/AHA and
National Health Data Dictionary standardised
deﬁnitions.
Exclusion criteria
Patients will be excluded if they die within 24 h of admis-
sion or do not usually reside within either region or
whom no follow-up data can be obtained; however, these
clients will still provide baseline incidence data. Cases
that do not fulﬁl the case deﬁnition of ADHF on review
of the notes will also be excluded, and recorded but will
not form baseline data.
Population/recruitment of subjects
A dedicated research assistant will recruit consecutive
patients who present acutely to either hospital or trans-
ferred from remote Indigenous communities from the
emergency clinical screen and medical admission lists for.
Of these, clients who are Aboriginal, or non-Aboriginal,
have a documented urban residence and reside in remote
communities will be followed. The participants will also be
drawn from inpatients who develop acute symptoms while
in hospital for other reasons. Flyers will be posted in emer-
gency, wards, intensive care and a brief presentation will
be made to the medical and nursing staff at relevant units.
Referrals from hospital staff in this form will be a second-
ary recruitment strategy. For retrospective audit, lists of
individuals will be generated through hospital separation
and CCU admissions data for the years 2011 and 2012.
The approved research assistant in each site will perform
this. An independent physician will review uncertain cases.
Data collection and storage
Data will be collected on a standardised case note extrac-
tion form developed during phase I of the project.
Information will be accessed through multiple sources
including hospital records, PHC clinic records, specialist
databases and record systems maintained by visiting dis-
trict medical ofﬁcers. The period of interest for data col-
lection will be 0–12 months after discharge following
documented ADHF. Data deﬁnitions will be standardised
and widely accepted case and outcome deﬁnitions as
outlined in the ACC Clinical Data Standards.9–11 31–37
All cases that demonstrate ambiguity in data deﬁnitions
or outcome data will initially be discussed with site
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investigator; if ambiguity persists, the principal investiga-
tor and a locally convened panel of the research team
will review, and consensus sought.
Measurement of performance
Phase I involves prospectively auditing admitted clients
hospital records. Phase II involves further assessment of
performance and will involve the auditing of client
records held at remote community health centres,
urban PHC centres, specialists’ records, hospital
records and outpatient and cardiac rehabilitation ﬁles.
Files are coded and stored by three health providers, NT
Department of Health and Community Services (DHCS
—ASH/RDH), PHC records and NT Cardiac Services
Pty Ltd. NT DHCS hospital separation data, hospital
records coding and storage of data follow a nationwide
format. PHC records will also be accessed to complete
the secondary prevention and follow-up components of
the audit and is subject to variability. NT Cardiac, main
provider of cardiac diagnostics and outpatient care, data-
bases and coronary intervention information systems
holds a range of clinical and cardiac investigation/inter-
vention (angiography, coronary stenting, echocardiog-
raphy, stress testing) information. This information will
be used to complete the data collection sheet for each
patient ﬁle. Denominator and numerator values for KPI
will be based on standardised values from ACC/AHA
guidelines, local laboratory speciﬁcation for biochemical
Figure 1 International
Classification of Diseases
(ICD)-10 of the circulatory system.
Primary screening includes codes
I42, I43 and I50. Secondary
screening involved acute
decompensated heart failure
during index admission with
highlighted codes.
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tests and Australian accrediting bodies for invasive and
non-invasive investigations. Overall performance will be
compared with the National benchmark for CHF out-
comes. As this is subject to change, the broad principals
will include CSANZ, Heart Foundation and locally pub-
lished studies that involve a public tertiary HF referral
centre from any of the six states in Australia. We will also
seek the opinion of several local leading HF clinicians
should there be issues standardising these benchmarks.
Participant follow-up
Clients will be followed up to determine subsequent hos-
pitalisation, major medical events and interventions.
Similar ICD codes for acute CHF will be used for
Figure 2 Design of the NTHFI-CA involved four steps: (A) using a set of standardised principles (blue box) and their attributes
(green box) we formulated outlines for each performance attribute (final column). CASPA shaped many aspects of design and
implementation attributes; (B) four basic factors shaped the broad study outline; (C) highlights the ethical considerations for
studies in the NT; (D) broad disease management goals for which performance measures hope to inform.30–33 CASPA, Central
Australian Secondary Prevention of Acute Coronary Syndromes; NT, Northern Territory; NTHFI-CA, Northern Territory Heart
Failure Initiative–Clinical Audit.
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screening information at 1, 6 and 12 months. Data
extraction will include a combination of case notes
review, medical databases and contact with PHC and
clients directly. Consent for this will be obtained during
the initial recruitment.
End points
The main indicators we are measuring cover a range of
domains across the spectrum of care for people with
ADHF. In brief variables include
▸ Baseline
– Demographics: age, sex, usual place of residence,
ethnicity;
– Background: medical history of CHF and treat-
ments, known risk factors and comorbidities;
– Symptom onset: time, nature, location, ﬁrst point of
contact with PHC, delay times to care.
▸ Prehospital management: appropriate medical/para-
medical assessment, provision of prehospital nitrates,
diuretics, ventilation and analgesia
▸ Emergency department: presentation, delas, biochem-
istry, investigations (chest X-ray, ECG, echocardiog-
raphy), therapeutics (assisted ventilation, intravenous
nitrates or diuretics); risk stratiﬁcation.
▸ Admission details: clinical examination, investigations,
management, complications during admission, per-
formance of phase I rehabilitation.
▸ Discharge: discharge diagnosis, discharge status, medi-
cation regime, referral to phase II cardiac rehabilita-
tion, discharge planning and referral to PHC provider.
▸ Outpatients
– Cardiac rehabilitation: attendance and completion
of cardiac rehabilitation.
– Secondary prevention: risk factor modiﬁcation, care
plan, cardiac education received, measurement of
and achievements of speciﬁed target goals for HF and
prevention of risk factors related to aetiology (eg, car-
diovascular disease, ie, smoking cessation, lipid
control, blood pressure control), complications.
– Self-management.
– Depression—PHQ9.
– Outcomes: readmission, major cardiovascular and
non-cardiovascular events, mortality.
– IT and telecommunications: availability, access and
type of mobile phone and Internet platforms.
Special Ethical Consideration and Adverse Events: cul-
tural and religious issues surrounding conﬁdentiality
and storage of human tissue are of signiﬁcant import-
ance for Indigenous clients. The NT is also host to a
diverse multiethnic population. We have thus chosen
not to store samples for future use. We have sought spe-
ciﬁc support from key Indigenous Community groups,
NT-DHCS, Cardiac Services, Remote and Primary
Health Services, Independent Health Services and
Indigenous Health Services, in advance. As primarily a
hospital and clinic ﬁle audit, this proposal does not dir-
ectly broach the issues of reciprocity, respect, equality,
responsibility, survival and protection, which are critical
in Indigenous research, conﬁrmation of which was
obtained through the ethics submission. We do not
anticipate any other adverse events. We have received full
ethics approval to conduct the study by Central Australia and
Top End Human Research Committees.
Training and standardisation
This project requires access to data housed and main-
tained by NT DHCS and NT Cardiac Services. Hospital
Separation Data, Hospital Records and PHC Records
will be sought from NT DHCS and will be arranged
through PI’s in Darwin. In the event that PHC records
are housed within independent services (non-DHCS
clinics), appropriate consultation will be undertaken as
requested by the independent services themselves.
Formalised consent processes as directed by independ-
ent services will be followed. If they wish to perform the
audit themselves, as a training and quality assurance
process, appropriate training and support will be pro-
vided by the research team. All staff recording informa-
tion will be briefed by training staff from the CASPA
study and undergo education in variability or data
recording, ambiguous data and differing case records,
ICD-10 classiﬁcation, ACC/AHA guidelines for KPI31
and NHMRC good clinical practice as the minimum
requirement. Addressing ambiguity has been discussed
under data collection and storage.
Expected sample size
On the basis of generated hospital separation and CCU
statistics, 2009, for ASH of 113 and RDH of 450 patients,
the sample population will be approximately 150
patients with ADHF at ASH and 500 matched at RDH in
the time period 2009. Of the ASH separations, 99 (88%)
are identiﬁed as being indigenous. The matched (ethni-
city and gender) RDH sample extrapolates to 180
(40%), Aboriginal clients in phase II. As data will be col-
lected on three separate occasions for each patient, a
robust dataset is expected to identify any signiﬁcant asso-
ciations between predictors and patient outcomes.
Findings from this investigation will also inform the
development of more testable hypotheses in future
studies and appropriate sample sizes.
Statistical considerations
All generated data will be entered into and analysed
with SPSS V.11.5. Initial data analysis will be conducted
to assess for data quality including allowable ranges, data
structure and errors. Descriptive statistics for baseline
participant characteristics, diagnostics and therapeutics
within highlighted domains will be calculated and pre-
sented as means (SD), IQR for continuous data and
count (per cent) for categorical data. Univariate
between group analyses will be performed using t tests
for continuous variables, and χ2 tests of association for
categorical variables. For study outcome measures, a
type 1 error rate of α=0.05 will be used to test for statis-
tical signiﬁcance. A generalised mixed-effects model
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approach will be used in the analysis of repeated mea-
sures for continuous and categorical outcomes.
Mixed-effects models take into account the interindivi-
dual differences in intraindividual change with repeated
responses and use all the available data on each partici-
pant. Mixed models are also unaffected by randomly
missing data and therefore do not require imputation
methods.42 The model-building strategy will include
ﬁtting nested models by sequentially adding blocks of
predictor variables: sociodemographics, comorbid disor-
ders and factors related to health service interventions.
Interaction terms that are considered to be potentially
important from a clinical perspective will be tested and
remain in ﬁnal models if signiﬁcant. Predicted estimates
of outcomes at each time point will be calculated using
ﬁtted models of the data in order to examine patterns
of individual change. To interpret effect sizes and preci-
sion for categorical outcomes, ORs and CIs will be
calculated.
DISCUSSION
The NTHFI-CA represents one of a few opportunities
offered for longitudinal studies designed to extract data
that inform service development. Information gathered
has to be relevant for current and future needs. It is dif-
ﬁcult to determine service factors beyond ﬁve yearly
intervals. To compensate for this, there have been mea-
sures taken to set infrastructure and standardise proto-
cols to facilitate episodic updates in information as well
as ensuring reproducibility of study design and imple-
mentation. With the actual study design, a series of steps
were taken. The ﬁrst step was establishing basic princi-
ples for deﬁning the disease (ﬁgure 1, see online sup-
plementary appendix A). The second step involved
standardising principles for attributes in KPI, that is,
care dimensions (ﬁgure 2A, see online supplementary
appendices B and C) and the study care domains to be
tested, in this case six (ﬁgure 2B). The third step
involved addressing the broad NT health goals and
research conducted in Indigenous population to steer
implementation within ﬁve key priorities (ﬁgure 2C).
The fourth step is design of disease management
systems in the NT context from the available evidence
(ﬁgure 2D, see online supplementary appendix D).
The resultant study pathway is highlighted in Figure 3.
The speciﬁc study in greater detail are explored.
The ACC/AHA has released several position statements
to standardise the process of developing, assessing, imple-
menting performance measures and disease manage-
ment systems.30–33 From this consensus-driven platform,
we identiﬁed the target disease, population and explored
standardised measures that inform the observation for
the required time period. The NTHFI-CA is deﬁned for
all stages and causes of CHF, for NT resident population
who receive care within six domains of treatment. This
broad deﬁnition partly relates to uncertainties on actual
CHF demographics, and as the yearly admission is
unlikely to exceed 500, will not lead to signiﬁcant difﬁcul-
ties in enrolment. To determine the performance mea-
sures, we again explored the position statement. The
authors rated 27 potential measures on 13 dimensions
using a ﬁve-point Likert scales.31 If a KPI received full
committee support with a score of at least 3, it was
advanced. The process concluded with 7 inpatients’ and
12 outpatients’ measures. These KPI informed ﬁve
dimensions of care encompassing: diagnostics, patient
education (including prognosis and aetiology), treat-
ment, and self-management (for inpatient and out-
patient) and monitoring of disease status (for outpatients
only).31 This statement did not, however, focus on out-
comes as the design was shaped to assist physicians
improve care. We have included outcomes, as this is the
strongest indicator of funding for vulnerable groups
beyond the conventional block funding models. To deter-
mine the ﬁnal KPI, several additional points were
considered.
1. Existing studies: Several recent databases stand as land-
mark achievements in HF epidemiology and have con-
ﬁrmed clinical understanding of evidence base and
positive outcomes.9–11 35 37 43 Interestingly Krumholz
et al30 pointed out a disparity between what is conven-
tionally accepted evidence and its generalisabilty. This
is particularly so for the NTwhere there are signiﬁcant
non-traditional factors that impact on the delivery of
evidence-based care and affect outcomes. While it
would be unreasonable to propose reconducting large
CHF studies to incorporate an increasingly diverse
group of patients, we have come to realise that the
heart of these matters is to develop an intrinsic under-
standing of the underlying regional demographic dif-
ferences and service delivery dynamics to be able to
formulate informed decisions in implementing the
necessary measures, be they simple or more complex.
Developing the necessary KPI in these settings is a
challenge as there is a divide between perceived
optimal care and realistic and deliverable care that, in
fact, is optimal for the region. From this, it was evident
that some measures needed to be rested (eg, treat-
ment optimisation) and others added (eg, the dimen-
sion of technology).
2. NT experience: The CASPA study was groundbreaking
in the sense that it allowed for the ﬁrst-time explor-
ation of ACS/cardiovascular KPI in Central Australia.
The list was formulated from an extensive search of
available national and international clinical guide-
lines, national health priority area indicators and
reports and with reference to National Health
Performance Committee guidelines and further aug-
mented by performance measures used in published
quality improvement projects. Three priorities—
process of care, target achievement and outcome
indicators for the treatment and prevention were
generated. This list underwent scrutiny by 60 key sta-
keholders, key external content experts and the
research team through mailed questionnaires and a
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workshop convened in Alice Springs. Each stake-
holder was asked to grade each potential indicator
according to a number of criteria: strength of evi-
dence; feasibility of measurement; plausibility of
effects from quality improvement; impact on out-
comes and an assessment of the overall utility of the
measure. Results were collated and analysed for each
indicator (overall grading) and for each of the ﬁve
criteria across each indicator. Indicators that were
graded as high priority, frequently recorded, very
plausible and will have a large impact or better were
included in the ﬁnal list (average score on grading
scale ≥4). Indicators that demonstrate an across cri-
teria grade of less than 4, but was assessed by key sta-
keholders as a high or essential priority within the
overall (utility) rating, were scrutinised by the project
team and included as decided by consensus. Data
speciﬁcations were then developed according to
internationally standardised deﬁnitions. Subsequent
data collection tools were developed and piloted in a
number of hospital and PHC records (n=20) and
implemented. The spill-over knowledge assisted
greatly in the NTHFI-CA design.
Combining this local and international experience,
with the standardised ACC position,31 a conceptual
framework KPI reﬂecting six critical domains for treat-
ment delivery and ﬁve principal dimensions of care
evolved (ﬁgure 3). All these well-established performance
measures were individually scrutinised and included or
rested. Level of evidence was the predominant scrutinis-
ing theme in the second phase. The less validated ‘local
knowledge’ and NT health priorities were additional con-
siderations. Study investigators made the decisions on
these. Several less well-established indicators were
included through recent understanding and develop-
ment of self-management and IT-based solutions.14 In
direct contrast to intervention-themed databases,34 35
focus on speciﬁcs in the treatment dimension was given a
lower priority (see online supplementary appendices E
and F). Figure 4 describes this in greater detail.
Further rationale for speciﬁc KPI inclusion or exclu-
sion are as follows: Domain 1: demographics are at the
heart of this study. Validated KPI derived from CASPA
were used to extract race, culture, language and support
networks; further expansion was made in the dimension
of HF aetiology with emphasis on ischaemic, hypertensive
Figure 3 Trial protocol and
study pathways.
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as well as rheumatic and alcohol-induced causes. Data on
tertiary referral centres were collected, as there were two
main cardiac surgical referral hospitals. Decision referral
patterns vary with the treating physician practices as well
as waiting list and urgency. It is established that decisions
on percutaneous or surgical revascularisation and valvu-
lar restoration or replacement differ at these sites on
physician, group consensus and expertise at the respect-
ive sites. Details on primary care physician, pharmacy,
residence and principal next of kin were deemed import-
ant as local and ethnicity were deemed factors in service
uptake and delivery. Furthermore, access to primary care
could determine: admission, re-admission burden and
early measures to prevent deterioration; Domain 2–5:
a comprehensive medical history of all systems were
included to establish the overall need for chronic
medical service needs and factors preventing use or
uptake of HF pharmacology, cardiac rehabilitation or
referral for invasive management. Biochemistry details
were included to establish pattern of establishing HF aeti-
ology and outpatient risk for adverse events. Methods for
estimating epidermal growth factor receptor was
obtained as much recent work raises validity of estimated
measures with illness and demographics, which subse-
quently alter prescribing practices and outcomes.11 12 44
KPI for depression were expanded, as a high burden was
noted in CASPA, this also being a signiﬁcant factor in
many dimensions of self-care and compliance. In hos-
pital, discharge and outpatient indicators were designed
to reﬂect the potential blocks to maximising proven
pharmacological prescription and access to cardiac
rehabilitation; at the core of these were reasons for non-
prescription or subtherapeutic prescription. The actual
speciﬁcs on medication titration across all domains were
rested. It is noted that care and resources are needed to
titrate many variables in CHF care, for example, ββ and
ACE-I (see online supplementary appendix E, F). This
information can be extrapolated from frequency of
contact with medical practitioner and central pharmacy
prescription slips. Appropriate early therapeutics—to
prevent further heart muscle damage, good symptom
relief and minimising iatrogenic adverse effects such as
renal dysfunction and electrolyte derangements are
within the control of the health systems and builds client
conﬁdence, and are considered vital. Domain 6: overall,
we felt, in the community, that the greatest value in the
Figure 4 Performance measures within each treatment dimensions divided into mild and moderate or greater acute
decompensated heart failure.
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performance measures related to two critical aspects—
impacts on the overall health system (strain and morale)
and contributors to poor outcomes (client and non-
client). Post hospital access to services and blocks to refer-
rals (non-client) and self-management (client) are
factors related to efﬁciency, planning and client educa-
tion. Investment in these dimensions would not increase
strain on resources, with potential beneﬁt.
Data collection instrument was via Case Report Forms
(CRF) designed for a combination of retrospective and
prospective audit from combination of several studies
such as CASPA and WHICH. The Baker IDI, Flinders
University and SAHMRI have extensive track record in
electronic CRF. This was greatly beneﬁcial and reduced
challenges faced at stage 2. At present, a considerable
research work is conducted through the Menzies School
of Health Research. As part of this initiative, we have
begun the process of developing dedicated ofﬁce to
conduct studies across the cardiac and renal axis. Part of
this also involved staff training in good clinical practice
and transfer of knowledge from partners to stand as an
independent entity.i
Indigenous health in the NT requires a special focus.
Australia has seen the ﬁrst Indigenous premier in 2013
and a measured but controversial statement of removing
the Indigenous ministerial portfolio was “there are
numerous ministers for many areas and one for all
Indigenous affairs”. Current sentiments that move away
from race-based programmes are encouraged but with
caution. We clarify that out approach does not target
any speciﬁc communities but is based on needs. It is
unfortunate that disadvantaged communities are also
marginalised in large studies partly for language, cul-
tural and perceived compliance issues. In this case, the
Indigenous community represents a signiﬁcant group in
Australian society who have despairingly worse out-
comes. The desire to preserve one’s traditional culture
in an ever-modernising world poses huge challenges for
these communities and health systems. Poor understand-
ing could lead to stereotyping that could brand some
behaviour as recalcitrant, adding to the vicious circle.
Respecting these beliefs and tailoring care in lieu of
these factors, we were able to advance the CASPA study.
This was carried out through acknowledgement of
several sensitive areas in the ethics application; Equality
—the overarching aims of the research project is based
within a framework driven by questions of equality in
the provision of healthcare across the continuum for all
patients regardless of ethnicity, gender or age, and one
based on need as demonstrated by clinical determinants;
Survival and Protection—we also recognise that chronic
disease research and epidemiology has tended to con-
tribute to deﬁcit approaches to individual pathology,
that is, disease is due to bad behaviour. Less focus has
been afforded the potential successes and failures in
health systems, as contributors to differential outcomes
for populations based on ethnicity; Respect—we feel that
information generated within this project and the pro-
cesses developed have the potential to contribute to
community-directed health service redevelopment and
quality improvement activities; Reciprocity—we feel that
this work may identify failures in health systems and
therefore identify obligations that are being unmet by
systems themselves; Responsibility—reframing the gaze of
health inequality, from individual-focused deﬁcits to
system failures stands as the key principle on which this
extensive work is based, and is a direct effort at ensuring
that exploring health inequalities does not undermine
and harm Indigenous individuals and communities.
These principles may play great importance to future
research practices in these areas.
Interim analysis will be conducted at the 6-month
mark. It is anticipated at this point lessons learnt and
spill-over knowledge from the ongoing CASPA-ACS inter-
vention study may direct minor modiﬁcations to the
existing CRF. One such area is increasing the KPI in
domains 1, 2 and 6 to better understand the barriers to
accessing primary care. CHF, an ambulatory case-
sensitive condition, can largely be managed in the com-
munity with the application of appropriate and timely
preventive care and early disease management. The
issues that remain unclear at this point are the adequacy
and the barriers for accessing such care in each of the
remote communities. Of interest, Ansari et al noted that
a lack of timely and effective care had an impact on
admission rates in rural Victoria particularly among
lower socio-economic groups.45 46 A similar understand-
ing in the NT could impact on how we allocate resources
in the future.
Measuring performance is not an end in its own right
and clinical indicators and their measurement alone are
not sufﬁcient to change behaviour in service provision
and quality improvement. They must be supplemented
with key educational activities (eg, provision of continu-
ous and sustained feedback of results to all levels of
service provision), processes to sustain continuous moni-
toring and assessment and to inform policy development
on a local and regional level. Clearly deﬁned dissemin-
ation processes and involvement of Aboriginal Health
Workers, hospital-based and community-based nurses,
allied health professionals and clinicians are essential if
practice is to change. Engaging non-governmental
(NGO) service providers, data coders, quality improve-
ment staff, NGOs (NHF NT Division, Healthy Living
NT), Division of General Practice/PHC and consumer
representatives in the development phase of the project
so as to ensure alignment between proposed indicators
and local needs. The dissemination of key ﬁndings
through key advisory/research institutions will also
increase the awareness nationally/globally and build
foundations for future competitive research funding.
Finally, we have also been in negotiations for the
iInformation on our partners and expertise can be found on the web
or via corresponding author.
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broader applicability of the ﬁndings of and tools utilised
within this project with the Australian Collaborative
Project (which seeks to measure PHC performance).
This stands as a critical method of project outcome
dissemination.
Limitations
Conducting clinical studies in the NT is in itself a limita-
tion: ﬁrst, the realisation of non-traditional risk factors,
which impact on management; second, as there are few
benchmarks as comparators and; ﬁnally, shortfalls in
research funding and infrastructure. While no system
has the perfect mix of resource input to match service
needs to answer this question, for this region, there will
be components within many aspects of the study, that is,
hypothesis generating, compared with the mainstream.
Nonetheless, following the accepted consensus and pro-
viding enough information to allow reproducibility are
accepted as a positive means for overcoming this limita-
tion. Examples of this were resting KPI that collate
in-depth information on medication dosing as per RCTs
and large HF databases.30–38 This study will not address
whether clinical trial prescribing practices are achieved;
instead, we are keen to determine whether there is a
system in place to facilitate this, which will be answered.
The infrastructure is also in place for the next step to
determine whether this can occur. We note that RCT
level outcomes relate to achieving prescribing practices
in the trials. As examples, online supplementary appen-
dix E/F highlight differences in two medications. As
noted, ββ titration is ideally carried out at two weekly
intervals and may not need biochemistry, while ACE-I
can be carried out at 3–7-day intervals and usually
requires assessment of basic biochemistry.ii Addition of
aldosterone blockers and other agents are further com-
plexities.ii We are hopeful that relevant information on
this will help steer the next phase, an intervention clin-
ical study. This study relied on lessons from ACS study
conducted greater than 5 years ago. Unanticipated
changes that cannot be standardised could act as con-
founders, which will only be revealed in time; for
example, is potential drop off rate during follow-up. In
the standardisation of design—we did not use ﬁve-point
Likert scale, as the number of NT consultants was only
4. In addition the CHF task force position was compre-
hensive.31 Finally, clinical practice guidelines are well
established, as Krumholtz stated “guidelines are written
in a spirit of suggesting diagnostic or therapeutic inter-
ventions for patients in most circumstances. Accordingly,
signiﬁcant judgment by clinicians is required to adapt
these guidelines to the care of individual patients to
ensure accountability in these judgments an evidenced
based process is important”. The standardising of
clinical judgement and interpretation of guidelines
remains contentious and may be more noticeable with
fewer cardiologists. As such we intentionally left the cri-
teria for KPI reference broad. This will be narrowed, as
lessons are learnt and early data are analysed. This
should aid more focused and detailed assessments in
the future.
CONCLUSION
Achieving optimal care in the remote setting is no differ-
ent from urban settings. The ability to provide a con-
tinuum of care from presentation to post discharge
requires activation of proven KPI at each level of care. The
signiﬁcant differences in remote care revolve around the
interaction of service infrastructure, personnel, disease
burden and cultural sensitivities. As such the outcomes
limiting factors are variable and require exploration. The
potential gains of these ﬁndings in implementing early
and later secondary prevention of CHF and its sequelae
are undisputed. In addition, little information exists on
the provision and outcomes for CHF initiatives for
Indigenous populations, which are a signiﬁcant client base
in the remote setting. Even less is known about the post-
discharge care. The extent to which care is suboptimal
and the acute and long-term HF management among
Aboriginal clients could be contributing to the large and
growing cardiovascular mortality differentials seen
between Aboriginal and non-Aboriginal clients. Thus, the
development of meaningful, sustainable public health,
clinical and continuous quality improvement policy in the
provision of CHF care in the NTrequires urgent attention,
and must be used to drive the development of better
service delivery at the individual and health system levels.
It is anticipated that this work will highlight key areas of
disparity and inform the implementation of an interven-
tion study.
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